



## Clinical trial results:

### A Randomised, Double-blind, Placebo-controlled Study of Orally Administered BBT-401-1S in Subjects with Moderate to Severe Ulcerative Colitis, Incorporating a Response-Adaptive, Double-blind Extension Phase

#### Summary

EudraCT number	2020-003556-33
Trial protocol	PL
Global end of trial date	12 July 2022

#### Results information

Result version number	v1 (current)
This version publication date	02 June 2023
First version publication date	02 June 2023

#### Trial information

##### Trial identification

Sponsor protocol code	BBT401-UC-005
-----------------------	---------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04596293
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Bridge Biotherapeutics, Inc.
Sponsor organisation address	C's Tower #303, 58, Pangyo-ro 255beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea, Republic of,
Public contact	Clinical Trials Information, Bridge Biotherapeutics, Inc., +82 31 8092 3280, clinicaltrials@bridgebiorx.com
Scientific contact	Clinical Trials Information, Bridge Biotherapeutics, Inc., +82 31 8092 3280, clinicaltrials@bridgebiorx.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	12 July 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	12 July 2022
Global end of trial reached?	Yes
Global end of trial date	12 July 2022
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this study is to explore the efficacy of orally administered BBT-401-1S in inducing a clinical response in subjects with active UC.

Protection of trial subjects:

A subject was free to withdraw from the study at any time. In addition, a subject was withdrawn from dosing if any of the following criteria were met:

- change in compliance with any inclusion/exclusion criterion that was clinically relevant and affected subject safety as determined by the investigator (or designee)
- noncompliance with the study restrictions that might have affected subject safety or study assessments/objectives, as considered applicable by the investigator (or designee)
- any clinically relevant sign or symptom (including disease worsening) that, in the opinion of the investigator (or designee), warranted subject withdrawal.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 March 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Korea, Republic of: 3
Country: Number of subjects enrolled	Poland: 7
Country: Number of subjects enrolled	Ukraine: 27
Country: Number of subjects enrolled	United States: 1
Worldwide total number of subjects	38
EEA total number of subjects	7

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	38
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Subjects with:

- active UC for  $\geq 3$  months prior to Day 1
- inadequate response or disease relapse despite treatment of UC based on the local standard of care (randomised at Korean sites only)
- total Mayo score  $\geq 6$ , an endoscopic subscore  $\geq 2$ , a rectal bleeding subscore  $\geq 1$ , and a stool frequency subscore  $\geq 1$ , regardless of standard of care history

### Period 1

Period 1 title	Induction Phase
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor

Blinding implementation details:

- The placebo capsules were identical in appearance to BBT-401-1S.
- The same number of capsules were administered at each dosing occasion.
- There were the same number of dosing occasions within the induction and extension phases.
- Subjects, investigators, and other members of staff involved with the study (including those involved in clinical operations and study site monitoring) remained blinded to the treatment randomisation.

### Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

12 subjects were to receive placebo twice daily.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Placebo capsules were identical in appearance to BBT-401-1S capsules but with the active study drug replaced with microcrystalline cellulose.

At each dosing occasion, subjects received a total of 4 capsules orally. Subjects received study drug in the morning and evening.

Subjects received the first dose of study drug at the study site on Day 1 and were to self-administer the study drug away from the study site for 56 days.

Arm title	BBT-401-1S Once Daily and Placebo QD
-----------	--------------------------------------

Arm description:

12 subjects were to receive 800 mg BBT-401-1S once daily (QD) and placebo QD.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	BBT-401-1S 800 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

BBT-401-1S was supplied as white, opaque, hydroxypropyl methylcellulose capsules for oral administration. Each capsule of BBT-401-1S contained 200 mg BBT-401-1S with excipients.

Subjects received 4 capsules orally in the morning once daily.

Subjects received the first dose of study drug at the study site on Day 1 and were to self-administer the study drug away from the study site for 56 days.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Placebo capsules were identical in appearance to BBT-401-1S capsules but with the active study drug replaced with microcrystalline cellulose.

Subjects received 4 capsules of placebo orally in the evening once daily.

Subjects received the first dose of study drug at the study site on Day 1 and were to self-administer the study drug away from the study site for 56 days.

<b>Arm title</b>	BBT-401-1S Twice Daily
------------------	------------------------

Arm description:

12 subjects were to receive 800 mg BBT-401-1S twice daily (BID)

Arm type	Experimental
Investigational medicinal product name	BBT-401-1S 800 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

BBT-401-1S was supplied as white, opaque, hydroxypropyl methylcellulose capsules for oral administration. Each capsule of BBT-401-1S contained 200 mg BBT-401-1S with excipients.

Subjects received 4 capsules orally in the morning and 4 capsules in the evening.

Subjects received the first dose of study drug at the study site on Day 1 and were to self-administer the study drug away from the study site for 56 days.

Number of subjects in period 1	Placebo	BBT-401-1S Once Daily and Placebo QD	BBT-401-1S Twice Daily
Started	13	12	13
ITT Population	11	11	11
Completed	11	11	10
Not completed	2	1	3
Clinical progression	1	1	-
Consent withdrawn by subject	-	-	2

Adverse event, non-fatal	1	-	-
Other	-	-	1

## Period 2

Period 2 title	Extension Phase
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor

Blinding implementation details:

The placebo capsules were identical in appearance to BBT-401-1S.

- The same number of capsules were administered at each dosing occasion.
- There were the same number of dosing occasions within the induction and extension phases.
- Subjects, investigators, and other members of staff involved with the study (including those involved in clinical operations and study site monitoring) remained blinded to the treatment randomisation.

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Placebo

Arm description:

Subjects were to receive placebo twice daily.

Subjects who agreed to participate in the extension phase were to continue study drug administration while awaiting their clinical remission status from the local reader. Subjects were assigned to the treatment for the extension phase on receipt of their clinical remission status.

- Subjects who achieved clinical remission in the induction phase were to continue the same treatment.
- Subjects who did not achieve clinical remission in the induction phase and:

- 1) who received placebo BID were to receive 800 mg BBT-401-1S QD and placebo QD
- 2) who received 800 mg BBT-401-1S QD and placebo QD were to receive 800 mg BBT-401-1S BID
- 3) who received 800 mg BBT-401-1S BID were to continue the same treatment.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Placebo capsules were identical in appearance to BBT-401-1S capsules but with the active study drug replaced with microcrystalline cellulose.

At each dosing occasion, subjects received a total of 4 capsules orally. Subjects received study drug in the morning and evening.

<b>Arm title</b>	BBT-401-1S Once Daily and Placebo QD
------------------	--------------------------------------

Arm description:

Subjects were to receive 800 mg BBT-401-1S once daily (QD) and placebo QD.

Subjects who agreed to participate in the extension phase were to continue study drug administration while awaiting their clinical remission status from the local reader. Subjects were assigned to the treatment for the extension phase on receipt of their clinical remission status.

- Subjects who achieved clinical remission in the induction phase were to continue the same treatment.

- Subjects who did not achieve clinical remission in the induction phase and:
  - 1) who received placebo BID were to receive 800 mg BBT-401-1S QD and placebo QD
  - 2) who received 800 mg BBT-401-1S QD and placebo QD were to receive 800 mg BBT-401-1S BID
  - 3) who received 800 mg BBT-401-1S BID were to continue the same treatment.

Arm type	Experimental
Investigational medicinal product name	BBT-401-1S 800 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

BBT-401-1S was supplied as white, opaque, hydroxypropyl methylcellulose capsules for oral administration. Each capsule of BBT-401-1S contained 200 mg BBT-401-1S with excipients.

Subjects received 4 capsules orally in the morning once daily.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Placebo capsules were identical in appearance to BBT-401-1S capsules but with the active study drug replaced with microcrystalline cellulose.

Subjects received 4 capsules of placebo orally in the evening once daily.

<b>Arm title</b>	BBT-401-1S Twice Daily
------------------	------------------------

Arm description:

Subjects were to receive 800 mg BBT-401-1S twice daily (BID).

Subjects who agreed to participate in the extension phase were to continue study drug administration while awaiting their clinical remission status from the local reader. Subjects were assigned to the treatment for the extension phase on receipt of their clinical remission status.

- Subjects who achieved clinical remission in the induction phase were to continue the same treatment.
- Subjects who did not achieve clinical remission in the induction phase and:
  - 1) who received placebo BID were to receive 800 mg BBT-401-1S QD and placebo QD
  - 2) who received 800 mg BBT-401-1S QD and placebo QD were to receive 800 mg BBT-401-1S BID
  - 3) who received 800 mg BBT-401-1S BID were to continue the same treatment.

Arm type	Experimental
Investigational medicinal product name	BBT-401-1S 800 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

BBT-401-1S was supplied as white, opaque, hydroxypropyl methylcellulose capsules for oral administration. Each capsule of BBT-401-1S contained 200 mg BBT-401-1S with excipients.

Subjects received 4 capsules orally in the morning and 4 capsules in the evening.

Number of subjects in period 2	Placebo	BBT-401-1S Once Daily and Placebo QD	BBT-401-1S Twice Daily
Started	11	11	10
Completed	11	10	8
Not completed	0	1	2
Consent withdrawn by subject	-	1	2



## Baseline characteristics

### Reporting groups

Reporting group title	Placebo
Reporting group description: 12 subjects were to receive placebo twice daily.	
Reporting group title	BBT-401-1S Once Daily and Placebo QD
Reporting group description: 12 subjects were to receive 800 mg BBT-401-1S once daily (QD) and placebo QD.	
Reporting group title	BBT-401-1S Twice Daily
Reporting group description: 12 subjects were to receive 800 mg BBT-401-1S twice daily (BID)	

Reporting group values	Placebo	BBT-401-1S Once Daily and Placebo QD	BBT-401-1S Twice Daily
Number of subjects	13	12	13
Age categorical Units: Subjects			
Adults (18-64 years)	13	12	13
Age continuous Units: years			
arithmetic mean	44.1	34.4	42.1
standard deviation	± 11.3	± 9.7	± 8.7
Gender categorical Units: Subjects			
Female	6	5	5
Male	7	7	8
Race Units: Subjects			
American Indian or Alaska Native	0	0	0
Black or African American	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
White	12	11	12
Asian	1	1	1
Ethnicity Units: Subjects			
Hispanic or Latino	0	0	1
Not Hispanic or Latino	13	12	12
Weight (kg) [b] Units: kg			
arithmetic mean	69.81	74.08	72.40
standard deviation	± 14.17	± 20.08	± 11.49

Reporting group values	Total		
Number of subjects	38		
Age categorical Units: Subjects			
Adults (18-64 years)	38		

Age continuous Units: years arithmetic mean standard deviation	-		
Gender categorical Units: Subjects			
Female	16		
Male	22		
Race Units: Subjects			
American Indian or Alaska Native	0		
Black or African American	0		
Native Hawaiian or Other Pacific Inlander	0		
White	35		
Asian	3		
Ethnicity Units: Subjects			
Hispanic or Latino	1		
Not Hispanic or Latino	37		
Weight (kg) [b] Units: kg arithmetic mean standard deviation	-		

### Subject analysis sets

Subject analysis set title	Placebo ITT
Subject analysis set type	Intention-to-treat
Subject analysis set description: The intent-to-treat (ITT) population included all subjects who received at least 1 dose of study drug, and who had a partial Mayo score recorded on Day 1 and at least 1 post-baseline Mayo score recorded.	
Subject analysis set title	BBT-401-1S Once Daily + Placebo Once Daily ITT
Subject analysis set type	Intention-to-treat
Subject analysis set description: The intent-to-treat (ITT) population included all subjects who received at least 1 dose of study drug, and who had a partial Mayo score recorded on Day 1 and at least 1 post-baseline Mayo score recorded.	
Subject analysis set title	BBT-401-1S Twice Daily ITT
Subject analysis set type	Intention-to-treat
Subject analysis set description: The intent-to-treat (ITT) population included all subjects who received at least 1 dose of study drug, and who had a partial Mayo score recorded on Day 1 and at least 1 post-baseline Mayo score recorded.	

Reporting group values	Placebo ITT	BBT-401-1S Once Daily + Placebo Once Daily ITT	BBT-401-1S Twice Daily ITT
Number of subjects	11	11	11
Age categorical Units: Subjects			
Adults (18-64 years)	11	11	11
Age continuous Units: years arithmetic mean	47.0	35.0	42.1

standard deviation	± 9.6	± 9.9	± 9.1
--------------------	-------	-------	-------

Gender categorical Units: Subjects			
Female	4	4	5
Male	7	7	6
Race Units: Subjects			
American Indian or Alaska Native	0	0	0
Black or African American	0	0	0
Native Hawaiian or Other Pacific Inlander	0	0	0
White	11	10	10
Asian	0	1	1
Ethnicity Units: Subjects			
Hispanic or Latino	0	0	1
Not Hispanic or Latino	11	11	10
Weight (kg) [b] Units: kg			
arithmetic mean	72.14	75.72	70.47
standard deviation	± 14.15	± 20.20	± 10.15

## End points

### End points reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

12 subjects were to receive placebo twice daily.

Reporting group title	BBT-401-1S Once Daily and Placebo QD
-----------------------	--------------------------------------

Reporting group description:

12 subjects were to receive 800 mg BBT-401-1S once daily (QD) and placebo QD.

Reporting group title	BBT-401-1S Twice Daily
-----------------------	------------------------

Reporting group description:

12 subjects were to receive 800 mg BBT-401-1S twice daily (BID)

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects were to receive placebo twice daily.

Subjects who agreed to participate in the extension phase were to continue study drug administration while awaiting their clinical remission status from the local reader. Subjects were assigned to the treatment for the extension phase on receipt of their clinical remission status.

- Subjects who achieved clinical remission in the induction phase were to continue the same treatment.

- Subjects who did not achieve clinical remission in the induction phase and:

1) who received placebo BID were to receive 800 mg BBT-401-1S QD and placebo QD

2) who received 800 mg BBT-401-1S QD and placebo QD were to receive 800 mg BBT-401-1S BID

3) who received 800 mg BBT-401-1S BID were to continue the same treatment.

Reporting group title	BBT-401-1S Once Daily and Placebo QD
-----------------------	--------------------------------------

Reporting group description:

Subjects were to receive 800 mg BBT-401-1S once daily (QD) and placebo QD.

Subjects who agreed to participate in the extension phase were to continue study drug administration while awaiting their clinical remission status from the local reader. Subjects were assigned to the treatment for the extension phase on receipt of their clinical remission status.

- Subjects who achieved clinical remission in the induction phase were to continue the same treatment.

- Subjects who did not achieve clinical remission in the induction phase and:

1) who received placebo BID were to receive 800 mg BBT-401-1S QD and placebo QD

2) who received 800 mg BBT-401-1S QD and placebo QD were to receive 800 mg BBT-401-1S BID

3) who received 800 mg BBT-401-1S BID were to continue the same treatment.

Reporting group title	BBT-401-1S Twice Daily
-----------------------	------------------------

Reporting group description:

Subjects were to receive 800 mg BBT-401-1S twice daily (BID).

Subjects who agreed to participate in the extension phase were to continue study drug administration while awaiting their clinical remission status from the local reader. Subjects were assigned to the treatment for the extension phase on receipt of their clinical remission status.

- Subjects who achieved clinical remission in the induction phase were to continue the same treatment.

- Subjects who did not achieve clinical remission in the induction phase and:

1) who received placebo BID were to receive 800 mg BBT-401-1S QD and placebo QD

2) who received 800 mg BBT-401-1S QD and placebo QD were to receive 800 mg BBT-401-1S BID

3) who received 800 mg BBT-401-1S BID were to continue the same treatment.

Subject analysis set title	Placebo ITT
----------------------------	-------------

Subject analysis set type	Intention-to-treat
---------------------------	--------------------

Subject analysis set description:

The intent-to-treat (ITT) population included all subjects who received at least 1 dose of study drug, and who had a partial Mayo score recorded on Day 1 and at least 1 post-baseline Mayo score recorded.

Subject analysis set title	BBT-401-1S Once Daily + Placebo Once Daily ITT
----------------------------	--

Subject analysis set type	Intention-to-treat
---------------------------	--------------------

Subject analysis set description:

The intent-to-treat (ITT) population included all subjects who received at least 1 dose of study drug, and who had a partial Mayo score recorded on Day 1 and at least 1 post-baseline Mayo score recorded.

Subject analysis set title	BBT-401-1S Twice Daily ITT
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
The intent-to-treat (ITT) population included all subjects who received at least 1 dose of study drug, and who had a partial Mayo score recorded on Day 1 and at least 1 post-baseline Mayo score recorded.	
<b>Primary: The clinical response at Day 57, as measured by a reduction of <math>\geq 3</math> points and <math>\geq 30\%</math> improvement from baseline of total Mayo score, which included a decrease in rectal bleeding subscore of <math>\geq 1</math> point or an absolute rectal bleeding subscore <math>\leq 1</math>.</b>	
End point title	The clinical response at Day 57, as measured by a reduction of $\geq 3$ points and $\geq 30\%$ improvement from baseline of total Mayo score, which included a decrease in rectal bleeding subscore of $\geq 1$ point or an absolute rectal bleeding subscore $\leq 1$ .
End point description:	
The primary efficacy endpoint was the clinical response rate at Day 57, as measured by a reduction of $\geq 3$ points and $\geq 30\%$ improvement from baseline of total Mayo score, which included a decrease in rectal bleeding subscore of $\geq 1$ point or an absolute rectal bleeding subscore $\leq 1$ .	
End point type	Primary
End point timeframe:	
Baseline to Day 57.	

End point values	Placebo ITT	BBT-401-1S Once Daily + Placebo Once Daily ITT	BBT-401-1S Twice Daily ITT	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	11	11	11	
Units: participants				
Clinical response rate at Day 57	7	6	6	

## Statistical analyses

<b>Statistical analysis title</b>	Clinical response rate: BBT-401-1S QD + Placebo QD
Comparison groups	Placebo ITT v BBT-401-1S Once Daily + Placebo Once Daily ITT
Number of subjects included in analysis	22
Analysis specification	Pre-specified
Analysis type	equivalence
P-value	= 1
Method	Fisher exact
Confidence interval	
level	95 %
sides	2-sided
lower limit	23.4
upper limit	83.3

<b>Statistical analysis title</b>	Clinical response rate: BBT-401-1S BID
-----------------------------------	--

Comparison groups	BBT-401-1S Twice Daily ITT v Placebo ITT
Number of subjects included in analysis	22
Analysis specification	Pre-specified
Analysis type	equivalence
P-value	= 1
Method	Fisher exact
Confidence interval	
level	95 %
sides	2-sided
lower limit	23.4
upper limit	83.3

---

**Secondary: Clinical remission at Day 57, as measured by a total Mayo score of  $\leq 2$  points, with no individual subscore exceeding 1 point**

End point title	Clinical remission at Day 57, as measured by a total Mayo score of $\leq 2$ points, with no individual subscore exceeding 1 point
End point description: Clinical remission at Day 57, as measured by a total Mayo score of $\leq 2$ points, with no individual subscore exceeding 1 point	
End point type	Secondary
End point timeframe: Baseline to Day 57	

End point values	Placebo ITT	BBT-401-1S Once Daily + Placebo Once Daily ITT	BBT-401-1S Twice Daily ITT	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	11	11	11	
Units: participants with clinical remission				
Clinical remission at Day 57	4	2	1	

**Statistical analyses**

<b>Statistical analysis title</b>	Clinical Remission at Day 57: BBT-401-1S QD + Plac
Comparison groups	Placebo ITT v BBT-401-1S Once Daily + Placebo Once Daily ITT
Number of subjects included in analysis	22
Analysis specification	Pre-specified
Analysis type	equivalence
P-value	= 0.6351
Method	Fisher exact

Confidence interval	
level	95 %
sides	2-sided
lower limit	2.3
upper limit	51.8

<b>Statistical analysis title</b>	Clinical Remission at Day 57: BBT-401-1S BID
Comparison groups	Placebo ITT v BBT-401-1S Twice Daily ITT
Number of subjects included in analysis	22
Analysis specification	Pre-specified
Analysis type	equivalence
P-value	= 0.3108
Method	Fisher exact
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.2
upper limit	41.3

**Secondary: Achievement of endoscopic remission at Day 57, as measured by a Mayo endoscopic subscore of 0 or 1.**

End point title	Achievement of endoscopic remission at Day 57, as measured by a Mayo endoscopic subscore of 0 or 1.
End point description:	
Achievement of endoscopic remission at Day 57, as measured by a Mayo endoscopic subscore of 0 or 1.	
End point type	Secondary
End point timeframe:	
Baseline to Day 57	

End point values	Placebo ITT	BBT-401-1S Once Daily + Placebo Once Daily ITT	BBT-401-1S Twice Daily ITT	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	11	11	11	
Units: participants				
Achievement of Endoscopic Remission at Day 57	5	4	3	

**Statistical analyses**

<b>Statistical analysis title</b>	Achievement of Endoscopic Remission: BBT-401-1S QD
Comparison groups	Placebo ITT v BBT-401-1S Once Daily + Placebo Once Daily ITT

Number of subjects included in analysis	22
Analysis specification	Pre-specified
Analysis type	equivalence
P-value	= 1
Method	Fisher exact
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.9
upper limit	69.2

<b>Statistical analysis title</b>	Achievement of Endoscopic Remission: BBT-401-1S BI
Comparison groups	Placebo ITT v BBT-401-1S Twice Daily ITT
Number of subjects included in analysis	22
Analysis specification	Pre-specified
Analysis type	equivalence
P-value	= 0.6594
Method	Fisher exact
Confidence interval	
level	95 %
sides	2-sided
lower limit	6
upper limit	61



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From screening (up to 28 days prior to Day 1) to follow-up visit (Day 71, +/- 7 days)

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.0
--------------------	------

### Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description: -

Reporting group title	BBT-401-1S Once Daily and Placebo Once Daily
-----------------------	--

Reporting group description: -

Reporting group title	BBT-401-1S Twice Daily
-----------------------	------------------------

Reporting group description: -

Serious adverse events	Placebo	BBT-401-1S Once Daily and Placebo Once Daily	BBT-401-1S Twice Daily
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 13 (0.00%)	1 / 12 (8.33%)	1 / 13 (7.69%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Surgical and medical procedures			
Abscess drainage			
subjects affected / exposed	0 / 13 (0.00%)	1 / 12 (8.33%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis ulcerative	Additional description: Occurred between the induction and extension phases		
subjects affected / exposed	0 / 13 (0.00%)	0 / 12 (0.00%)	1 / 13 (7.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Placebo	BBT-401-1S Once Daily and Placebo Once Daily	BBT-401-1S Twice Daily
Total subjects affected by non-serious adverse events subjects affected / exposed	2 / 13 (15.38%)	4 / 12 (33.33%)	7 / 13 (53.85%)
Investigations			
Lipase increased subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 12 (0.00%) 0	1 / 13 (7.69%) 1
Blood glucose increased subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 12 (0.00%) 0	0 / 13 (0.00%) 0
Coagulation factor decreased subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 12 (8.33%) 1	0 / 13 (0.00%) 0
Gamma-glutamyl transferase increased subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 12 (0.00%) 0	1 / 13 (7.69%) 1
Cardiac disorders			
Tachycardia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 12 (8.33%) 1	0 / 13 (0.00%) 0
Ventricular extrasystoles subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 12 (8.33%) 1	0 / 13 (0.00%) 0
Nervous system disorders			
Headache subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 12 (0.00%) 0	1 / 13 (7.69%) 1
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	1 / 12 (8.33%) 1	0 / 13 (0.00%) 0
Leukocytosis subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 12 (8.33%) 1	0 / 13 (0.00%) 0
General disorders and administration site conditions			

Pyrexia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 12 (8.33%) 1	0 / 13 (0.00%) 0
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 12 (8.33%) 1	0 / 13 (0.00%) 0
Hepatobiliary disorders Hepatitis subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 12 (8.33%) 1	0 / 13 (0.00%) 0
Skin and subcutaneous tissue disorders Rash subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 12 (0.00%) 0	1 / 13 (7.69%) 1
Renal and urinary disorders Proteinuria subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 12 (8.33%) 1	0 / 13 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)  Joint stiffness subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0  0 / 13 (0.00%) 0	0 / 12 (0.00%) 0  0 / 12 (0.00%) 0	1 / 13 (7.69%) 1  1 / 13 (7.69%) 1
Infections and infestations COVID-19 subjects affected / exposed occurrences (all)  Nasopharyngitis subjects affected / exposed occurrences (all)  Sinusitis subjects affected / exposed occurrences (all)  Peritonsillar abscess	0 / 13 (0.00%) 0  0 / 13 (0.00%) 0  0 / 13 (0.00%) 0	1 / 12 (8.33%) 1  1 / 12 (8.33%) 2  1 / 12 (8.33%) 1	1 / 13 (7.69%) 1  0 / 13 (0.00%) 0  0 / 13 (0.00%) 0

subjects affected / exposed	0 / 13 (0.00%)	0 / 12 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
09 April 2021	<p>Version 4.1, Korea</p> <ul style="list-style-type: none"><li>• Added that subjects must have had an inadequate response or disease relapse (despite treatment for ulcerative colitis according to the local standard of care) for inclusion in the study.</li><li>• Added that over-the-counter and prescription antidiarrhoeals and probiotics were excluded from 2 weeks prior to screening and for the duration of the study.</li><li>• Added that colonic dysplasia was exclusionary.</li><li>• Added that the presence or a history of cancer that had not been in full remission for <math>\geq 5</math> years are exclusionary, except for completely resected or treated squamous cell or basal cell carcinomas of the skin.</li><li>• Added that hypersensitivity to any of the active ingredients or excipients of BBT-401-1S or placebo was exclusionary.</li><li>• Added an additional visit on Day 126 in the extension phase for safety monitoring.</li><li>• Clarified the duration of the induction phase for subjects who subsequently progress into the extension phase.</li></ul>
02 August 2021	<p>Version 5.0</p> <ul style="list-style-type: none"><li>• Updated that rectally administered 5-aminosalicylic acid that had been stable for <math>&lt; 5</math> weeks was exclusionary.</li><li>• Clarified that concomitant medications for ulcerative colitis should have been maintained at a stable dose until the last dose of study drug.</li><li>• Added that over-the-counter and prescription antidiarrhoeals and probiotics are excluded for the duration of the study.</li><li>• Added guidelines for performing assessments and procedures during the coronavirus disease-2019 pandemic.</li></ul>
02 August 2021	<p>Version 5.1, Korea</p> <ul style="list-style-type: none"><li>• Updated that rectally administered 5-aminosalicylic acid that had been stable for <math>&lt; 5</math> weeks was exclusionary.</li><li>• Clarified that concomitant medications for ulcerative colitis should have been maintained at a stable dose until the last dose of study drug.</li></ul>

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported